Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × MK-8776 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Hodgkin Disease 1

Interventions

pembrolizumab 131 Paclitaxel 100 Gemcitabine 99 Carboplatin 84 Nivolumab 65 Docetaxel 62 Bevacizumab 62 Cisplatin 56 Pemetrexed 50 Fluorouracil 48 Cyclophosphamide 41 Cetuximab 41 trametinib 38 venetoclax 37 Leucovorin 37 Irinotecan 37 Sorafenib 35 Capecitabine 35 Ipilimumab 32 Dexamethasone 32 atezolizumab 30 Erlotinib Hydrochloride 28 Drug Therapy 27 130-nm albumin-bound paclitaxel 27 Epoetin Alfa 26 Doxorubicin 25 Oxaliplatin 24 Albumin-Bound Paclitaxel 23 Rituximab 22 Prednisone 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00779584 2018-08-27

MK-8776-002

Merck Sharp & Dohme LLC

Phase 1 Completed

45 enrolled 20 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡